MARKET

BTAI

BTAI

Bioxcel Therapeutics Inc
NASDAQ
2.070
-0.020
-0.96%
After Hours: 2.070 0 0.00% 19:45 12/05 EST
OPEN
2.120
PREV CLOSE
2.090
HIGH
2.169
LOW
2.051
VOLUME
267.75K
TURNOVER
--
52 WEEK HIGH
9.26
52 WEEK LOW
1.170
MARKET CAP
45.27M
P/E (TTM)
-0.1989
1D
5D
1M
3M
1Y
5Y
1D
Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions
Barchart · 3d ago
Weekly Report: what happened at BTAI last week (1124-1128)?
Weekly Report · 5d ago
Weekly Report: what happened at BTAI last week (1117-1121)?
Weekly Report · 11/24 09:33
BioXcel Therapeutics’ Igalmi supplement for new indication approved by FDA
TipRanks · 11/21 15:25
Weekly Report: what happened at BTAI last week (1110-1114)?
Weekly Report · 11/17 09:34
Analysts Conflicted on These Healthcare Names: Bioxcel Therapeutics (BTAI) and Day One Biopharmaceuticals (DAWN)
TipRanks · 11/13 15:30
BioXcel Therapeutics’ Q3 2025 Earnings and Clinical Updates
TipRanks · 11/13 04:18
BioXcel Therapeutics GAAP EPS of -$2.18 misses by $0.84
Seeking Alpha · 11/12 12:40
More
About BTAI
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics LLC, is focused on the development of medicines in immuno-oncology. Its advanced neuroscience candidate, BXCL501, is an investigational, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorder or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimer’s disease in the at-home setting and in care facilities. Its advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.

Webull offers BioXcel Therapeutics Inc stock information, including NASDAQ: BTAI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTAI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BTAI stock methods without spending real money on the virtual paper trading platform.